Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microecological Modulators for End-Stage Liver Disease
ChiCTR2600130122Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Aug 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of allogeneic fecal microbiota in hepatic disease, Cirrhosis and hepatic failure (5 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Overall liver function improvement rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
hepatic diseaseCirrhosishepatic failure
Beyond the preview
Go deeper on ChiCTR2600130122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130122.